Among them are phase 2 trials with the next‐generation CHK‐1 inhibitor prexasertib as a single agent in BRCA1/2 mutation‐associated breast or ovarian cancer and in patients with solid tumors with replicative stress or homologous repair deficiency. This evidence concerns the gene BRCA1 and ovarian carcinoma.